Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 December;47(4) > The Quarterly Journal of Nuclear Medicine 2003 December;47(4):223-37

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  USE OF RADIOLABELLED PEPTIDES FOR SCINTIGRAPHY IN NON-ONCOLOGIC DISEASESFREEfree


The Quarterly Journal of Nuclear Medicine 2003 December;47(4):223-37

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases

Sosabowsky J., Melendez-Alafort L., Mather S.

Nuclear Medicine Research Laboratory Department of Nuclear Medicine St Bartholomew’s Hospital, London, UK


FULL TEXT  


Radiolabelled pep­tides ­have sig­nif­i­cant poten­tial as radio­phar­ma­ceu­ti­cals for the diag­no­sis and ther­a­py of recep­tor-express­ing dis­eas­es. Methods ­have ­been devel­oped for label­ling pep­tides ­with a varie­ty of radio­nu­clides hav­ing a ­broad ­range of chem­i­cal and phys­i­cal prop­er­ties. These meth­ods ­include ­both ­direct (­where the radio­nu­clide is ­bound direct­ly to one or ­more ­atoms of the pep­tide struc­ture) and indi­rect tech­niques in ­which bifunc­tion­al ­coupling ­agents are ­employed. Although ­most com­mon­ly ­applied to ­date in the ­field of oncol­o­gy, a sig­nif­i­cant num­ber of appli­ca­tions in non-onco­log­i­cal dis­eas­es ­have ­also ­been pro­posed and ­these can be expect­ed to ­expand as the tech­nol­o­gy pro­gress­es. An over­view is pre­sent­ed of ­some pep­tide-recep­tor ­systems in radio­phar­ma­ceu­ti­cal devel­op­ment and the tech­niques ­which ­have ­been ­employed to radio­lab­el ­these pep­tides ­with iso­topes of ­iodine, yttri­um, indi­um, gal­li­um, cop­per and tech­ne­tium. While ­many of the exam­ples ­employed are ­derived ­from can­cer relat­ed indi­ca­tions, iden­ti­cal radio­phar­ma­ceu­ti­cal chem­is­try can ­also be ­applied to pep­tides ­with appli­ca­tions in the ­fields of immu­nol­o­gy, infec­tion and oth­er inflam­ma­to­ry con­di­tions.

top of page

Publication History

Cite this article as

Corresponding author e-mail